Azlocillin treatment of urinary tract infection in patients on haemodialysis.
Pharmacokinetic properties and clinical efficiency of azlocillin were investigated in three patients with terminal renal failure both during and without haemodialysis. All patients were treated for urinary tract infections with azlocillin 2 g three times daily for a period of ten days. Mean serum half-lives off dialysis were 251 min and on dialysis 202 min. Azlocillin clearances increased from a mean value of 58.7 ml/min off dialysis to 72.6 ml/min on dialysis. Urinary excretion of the total daily dose of azlocillin was less than 5% for all patients, but from day 2 onwards all patients had urine levels which were more than 8 times above the approximate MIC value of the infecting bacteria.
D000368:Aged; D001390:Azlocillin; D005260:Female; D006207:Half-Life; D006801:Humans; D007676:Kidney Failure, Chronic / Q000378:metabolism; D007700:Kinetics; D008297:Male; D008875:Middle Aged; D010406:Penicillins / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use*; D006435:Renal Dialysis; D014552:Urinary Tract Infections / Q000188:drug therapy*
D010406:Penicillins; D001390:Azlocillin